Published in Schizophr Bull on August 16, 2007
General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol Psychiatry (2008) 1.86
What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev (2009) 1.73
Clinical, functional, and intertask correlations of measures developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium. Schizophr Bull (2011) 1.67
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry (2012) 1.62
A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. Neuropsychology (2009) 1.49
Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls. Schizophr Bull (2010) 1.21
Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull (2008) 1.21
Cognition in mouse models of schizophrenia susceptibility genes. Schizophr Bull (2009) 1.11
Pathogenetic and therapeutic perspectives on neurocognitive models in psychiatry: A synthesis of behavioral, brain imaging, and biological studies. Indian J Psychiatry (2012) 0.95
Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull (2013) 0.94
Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment. Eur Arch Psychiatry Clin Neurosci (2013) 0.87
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res (2004) 3.57
Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry (2001) 2.95
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry (2000) 2.66
Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry (2006) 2.63
Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry (1997) 2.48
Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry (2001) 2.08
Computerized neurocognitive scanning: II. The profile of schizophrenia. Neuropsychopharmacology (2001) 1.97
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res (2006) 1.80
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2007) 1.67
General and specific cognitive deficits in schizophrenia. Biol Psychiatry (2004) 1.64
Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry (2002) 1.62
Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry (2003) 1.60
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry (2004) 1.58
A twin MRI study of size variations in human brain. J Cogn Neurosci (2000) 1.57
Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology (2006) 1.55
A six-factor model of cognition in schizophrenia and related psychotic disorders: relationships with clinical symptoms and functional capacity. Schizophr Bull (2004) 1.53
A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr Res (2006) 1.49
Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res (2005) 1.40
Cognitive experimental approaches to investigating impaired cognition in schizophrenia: a paradigm shift. J Clin Exp Neuropsychol (2002) 1.39
Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology (2004) 1.37
Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis (2000) 1.32
Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia. Schizophr Res (2004) 1.30
Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia. Schizophr Bull (2005) 1.24
Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology (2004) 1.23
Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry (2005) 1.14
NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res (2004) 1.14
The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. Psychopharmacology (Berl) (2006) 1.07
Confirmatory factor analysis of the WAIS-R in patients with schizophrenia. Schizophr Res (1998) 1.07
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) (2003) 1.06
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry (2005) 1.05
Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients? Schizophr Res (2006) 1.01
The Penn Conditional Exclusion Test (PCET): relationship to the Wisconsin Card Sorting Test and work function in patients with schizophrenia. Schizophr Res (2004) 1.00
The contribution of neuropsychology to psychiatry. Am J Psychiatry (1995) 1.00
Sensorimotor and cognitive slowing in schizophrenia as measured by the Symbol Digit Substitution Test. J Psychiatr Res (2005) 0.98
Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology (2003) 0.97
Factor structure of the Wechsler Adult Intelligence Scale-III in schizophrenia. Assessment (2002) 0.94
The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry (2003) 0.94
A brief cognitive assessment for use with schizophrenia patients in community clinics. Schizophr Res (2004) 0.93
Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull (1999) 0.92
Executive-frontal lobe cognitive dysfunction in schizophrenia: a symptom subtype analysis. Psychiatry Res (1998) 0.91
Assessing the neuropsychological profile of stable schizophrenic outpatients. J Neuropsychiatry Clin Neurosci (1996) 0.89
Long-term memory deficits in schizophrenia: primary or secondary dysfunction? Neuropsychology (2003) 0.87
Neurocognitive dimensions characterising patients with first-episode psychosis. Br J Psychiatry Suppl (2002) 0.84
D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Schizophr Res (1996) 0.84
Glucose effects on cognition in schizophrenia. Schizophr Res (2003) 0.81
Neuropsychological correlates of sustained attention in schizophrenia. Schizophr Res (1997) 0.80
Is Wisconsin Card Sorting Test performance related to 'working memory' capacity? Schizophr Res (1997) 0.79
Neuropsychological impairment and psychopathology in first-episode schizophrenic patients related to the early course of illness. Eur Arch Psychiatry Clin Neurosci (1998) 0.77
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry (2007) 4.44
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res (2004) 3.57
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry (2007) 2.98
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Patients with schizophrenia demonstrate dissociation between affective experience and motivated behavior. J Abnorm Psychol (2007) 2.08
A new perspective on anhedonia in schizophrenia. Am J Psychiatry (2012) 2.08
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction. Schizophr Res (2007) 1.98
Delay discounting in schizophrenia. Cogn Neuropsychiatry (2007) 1.94
Anticipatory vs. consummatory pleasure: what is the nature of hedonic deficits in schizophrenia? Psychiatry Res (2011) 1.91
General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol Psychiatry (2008) 1.86
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry (2013) 1.85
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res (2005) 1.73
Failure of schizophrenia patients to overcome salient distractors during working memory encoding. Biol Psychiatry (2010) 1.73
The construct of attention in schizophrenia. Biol Psychiatry (2008) 1.68
General and specific cognitive deficits in schizophrenia. Biol Psychiatry (2004) 1.64
Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology (2008) 1.64
Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry (2002) 1.62
Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biol Psychiatry (2010) 1.58
Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry (2005) 1.57
Decision-making impairments in the context of intact reward sensitivity in schizophrenia. Biol Psychiatry (2008) 1.55
A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull (2013) 1.52
A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr Res (2006) 1.49
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res (2010) 1.43
Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry (2007) 1.39
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am J Psychiatry (2009) 1.36
Schizophrenia in translation: the presence of absence: habenular regulation of dopamine neurons and the encoding of negative outcomes. Schizophr Bull (2006) 1.33
Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res (2004) 1.33
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res (2008) 1.30
Optimization of a goal maintenance task for use in clinical applications. Schizophr Bull (2012) 1.30
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull (2006) 1.30
Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr Bull (2006) 1.30
Patients with schizophrenia demonstrate inconsistent preference judgments for affective and nonaffective stimuli. Schizophr Bull (2010) 1.29
No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology (2005) 1.29
The speed of visual attention in schizophrenia: electrophysiological and behavioral evidence. Schizophr Res (2006) 1.26
Optimization and validation of a visual integration test for schizophrenia research. Schizophr Bull (2011) 1.26
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull (2003) 1.24
Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology (2010) 1.23
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
Impaired response selection in schizophrenia: evidence from the P3 wave and the lateralized readiness potential. Psychophysiology (2009) 1.23
Social/communication skills, cognition, and vocational functioning in schizophrenia. Schizophr Bull (2006) 1.21
Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls. Schizophr Bull (2010) 1.21
Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling. Neuropsychology (2011) 1.21
Relational and Item-Specific Encoding (RISE): task development and psychometric characteristics. Schizophr Bull (2011) 1.21
Impaired control of visual attention in schizophrenia. J Abnorm Psychol (2006) 1.19
The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates. Schizophr Res (2011) 1.18
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophr Res (2010) 1.15
The relationship between working memory capacity and broad measures of cognitive ability in healthy adults and people with schizophrenia. Neuropsychology (2013) 1.11
Emotion regulation abnormalities in schizophrenia: cognitive change strategies fail to decrease the neural response to unpleasant stimuli. Schizophr Bull (2013) 1.11
Another view of therapy for cognition in schizophrenia. Biol Psychiatry (2002) 1.11
Learning-related changes in brain activity following errors and performance feedback in schizophrenia. Schizophr Res (2007) 1.08
The Wisconsin Card Sorting impairment in schizophrenia is evident in the first four trials. Schizophr Res (2007) 1.07
Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia. Psychol Assess (2011) 1.05
The roles of reward, default, and executive control networks in set-shifting impairments in schizophrenia. PLoS One (2013) 1.04
The translation of cognitive paradigms for patient research. Schizophr Bull (2008) 1.03
A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry (2013) 1.03
Visuospatial attention in schizophrenia: deficits in broad monitoring. J Abnorm Psychol (2011) 1.02
Verbal and visual memory: characterizing the clinical and intermediate phenotype in schizophrenia. Schizophr Res (2008) 1.02
Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res (2012) 1.01
Dissociation of response and feedback negativity in schizophrenia: electrophysiological and computational evidence for a deficit in the representation of value. Front Hum Neurosci (2011) 1.01
Control of working memory content in schizophrenia. Schizophr Res (2011) 1.01
Set-shifting ability and schizophrenia: a marker of clinical illness or an intermediate phenotype? Biol Psychiatry (2008) 1.00
Optimistic bias in the perception of personal risk: patterns in schizophrenia. Am J Psychiatry (2005) 1.00
Toward the neural mechanisms of reduced working memory capacity in schizophrenia. Cereb Cortex (2012) 1.00
Imagining the future: degraded representations of future rewards and events in schizophrenia. J Abnorm Psychol (2011) 0.99
Working memory consolidation is abnormally slow in schizophrenia. J Abnorm Psychol (2005) 0.98
Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull (2006) 0.97
Attentional disengagement from emotional stimuli in schizophrenia. Schizophr Res (2011) 0.96
Factor structure of the Wechsler Adult Intelligence Scale-III in schizophrenia. Assessment (2002) 0.94
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry (2009) 0.92
Impaired visual working memory consolidation in schizophrenia. Neuropsychology (2009) 0.92
Hypothetical decision making in schizophrenia: the role of expected value computation and "irrational" biases. Psychiatry Res (2013) 0.91
Iconic decay in schizophrenia. Schizophr Bull (2010) 0.90
Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. Psychosomatics (2008) 0.89
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res (2011) 0.89
Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry (2011) 0.88
Kraepelin and Bleuler had it right: people with schizophrenia have deficits sustaining attention over time. J Abnorm Psychol (2012) 0.86
The spatial range of contour integration deficits in schizophrenia. Exp Brain Res (2012) 0.85
The processing of emotional stimuli during periods of limited attentional resources in schizophrenia. J Abnorm Psychol (2013) 0.85
Reduced susceptibility to confirmation bias in schizophrenia. Cogn Affect Behav Neurosci (2014) 0.84
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology (2010) 0.83
A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia. J Clin Psychopharmacol (2017) 0.82
Diagnosis of schizophrenia: consistency across information sources and stability of the condition. Schizophr Res (2012) 0.82
Response activation impairments in schizophrenia: evidence from the lateralized readiness potential. Psychophysiology (2011) 0.82
Optimizing vs. matching: response strategy in a probabilistic learning task is associated with negative symptoms of schizophrenia. Schizophr Res (2011) 0.82
Differential effects of emotional information on interference task performance across the life span. Front Aging Neurosci (2010) 0.81
Enuresis as a premorbid developmental marker of schizophrenia. Brain (2008) 0.80
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. J Clin Psychopharmacol (2015) 0.80
Common and specific cognitive deficits in schizophrenia: relationships to function. Cogn Affect Behav Neurosci (2014) 0.80
Cognition-emotion interactions are modulated by working memory capacity in individuals with schizophrenia. Schizophr Res (2012) 0.79